Form 4: Apellis Pharmaceuticals Acquired by Biogen

Apellis Pharmaceuticals has been acquired by Biogen in a transaction effective May 14, 2026, resulting in the delisting of its common stock.

Summary

• Apellis Pharmaceuticals, Inc. (APLS) completed its merger with a subsidiary of Biogen Inc. on May 14, 2026.
• Shareholders receive $41.00 per share in cash plus one non-transferable contingent value right (CVR) per share.
• The CVR entitles holders to potential additional payments of up to $4.00 per share upon the achievement of specific milestones.
• All outstanding equity awards, including RSUs and stock options, were either cashed out, converted into CVRs, or cancelled depending on their exercise price and vesting status.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive outcome for shareholders, as the acquisition provides a definitive cash exit and potential upside through CVRs, though the cancellation of out-of-the-money options is a standard but negative outcome for some employees.

Positives

• Shareholders received a definitive cash consideration of $41.00 per share.
• The inclusion of a CVR provides potential upside of up to $4.00 per share if specific milestones are met.
• The compensation committee certified a 200% payout for certain performance-based RSUs based on relative TSR performance.

Negatives

• Stock options with an exercise price of $45.00 or greater were cancelled without any consideration.
• The company has ceased to be an independent publicly traded entity.

Risks

• The $4.00 per share CVR value is contingent upon future milestones and is not guaranteed.
• Payments under the CVR are subject to tax withholding and potential reduction based on the terms of the CVR agreement.

Future Outlook

The company is now a wholly owned subsidiary of Biogen. Future value for former shareholders is limited to the potential milestone payments associated with the CVRs.

Management Comments

• The compensation committee certified that the Relative TSR as of May 8, 2026, was at the 93.3rd percentile, resulting in a 200% payout for applicable performance-based RSUs.

Industry Context

StockSavvy.ai notes that this acquisition reflects the ongoing trend of large-cap biopharmaceutical companies (Biogen) consolidating mid-cap biotech firms (Apellis) to bolster their pipelines, particularly in specialized therapeutic areas.

Comparison to Industry Standards

• The use of CVRs in this deal is consistent with recent M&A activity in the biotech sector, where acquirers use milestone-based payments to bridge valuation gaps regarding clinical trial outcomes.
• The $41.00 cash offer represents a standard premium-based exit for shareholders in the current biotech M&A environment.

Corporate Governance

Stakeholder Impact

• Shareholders receive cash and CVRs.
• Employees with unvested or out-of-the-money options face potential loss of value.
• The company ceases to be a publicly traded entity.

Next Steps

• Distribution of cash consideration to shareholders.
• Monitoring of milestone achievements for potential CVR payouts.

Key Dates

Keywords

Apellis Pharmaceuticals, Biogen, Merger, Acquisition, APLS, Contingent Value Right, Tender Offer